616 related articles for article (PubMed ID: 16330284)
1. Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98.
International Commission on Radiological Protection
Ann ICRP; 2005; 35(3):iii-vi, 3-50. PubMed ID: 16330284
[TBL] [Abstract][Full Text] [Related]
2. [The recommendations of the International Commission on Radiological Protection (ICRP) for high-dose-rate brachytherapy and for permanent prostatic implants].
Cosset JM; Pinillos-Ashton L; Mettler F;
Cancer Radiother; 2004 Nov; 8 Suppl 1():S50-5. PubMed ID: 15679247
[TBL] [Abstract][Full Text] [Related]
3. Radiation exposure after permanent prostate brachytherapy.
Cattani F; Vavassori A; Polo A; Rondi E; Cambria R; Orecchia R; Tosi G
Radiother Oncol; 2006 Apr; 79(1):65-9. PubMed ID: 16564593
[TBL] [Abstract][Full Text] [Related]
4. [Radiation protection issues in brachytherapic treatment of prostatic cancer].
Bellia M; Bellia S; Ciantia F; Luca N; Serafino L; Occhipinti A; Bona R; Mannino G
G Ital Med Lav Ergon; 2007; 29(3 Suppl):781-3. PubMed ID: 18409959
[TBL] [Abstract][Full Text] [Related]
5. Protecting people against radiation exposure in the event of a radiological attack. A report of The International Commission on Radiological Protection.
Valentin J;
Ann ICRP; 2005; 35(1):1-110, iii-iv. PubMed ID: 16164984
[TBL] [Abstract][Full Text] [Related]
6. Assessment of radiation safety instructions to patients based on measured dose rates following prostate brachytherapy.
Dauer LT; Zelefsky MJ; Horan C; Yamada Y; St Germain J
Brachytherapy; 2004; 3(1):1-6. PubMed ID: 15110306
[TBL] [Abstract][Full Text] [Related]
7. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
[TBL] [Abstract][Full Text] [Related]
8. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
Crook JM; Potters L; Stock RG; Zelefsky MJ
Brachytherapy; 2005; 4(3):186-94. PubMed ID: 16182218
[TBL] [Abstract][Full Text] [Related]
9. [Brachytherapy for prostate cancer: old concept, new techniques].
Cosset JM; Flam T; Thiounn N; Rosenwald JC; Pontvert D; Timbert M; Solignac S; Chauveinc L
Bull Cancer; 2006 Aug; 93(8):761-6. PubMed ID: 16935780
[TBL] [Abstract][Full Text] [Related]
10. [Brachytherapy for prostate cancer: high dose rate or low-dose rate?].
Cosset JM; Haie-Meder C
Cancer Radiother; 2005 Dec; 9(8):610-9. PubMed ID: 16226473
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
12. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
13. Prevention of high-dose-rate brachytherapy accidents. ICRP Publication 97.
Valentin J;
Ann ICRP; 2005; 35(2):1-51. PubMed ID: 16243099
[TBL] [Abstract][Full Text] [Related]
14. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer.
Tharp M; Hardacre M; Bennett R; Jones WT; Stuhldreher D; Vaught J
Brachytherapy; 2008; 7(3):231-6. PubMed ID: 18579446
[TBL] [Abstract][Full Text] [Related]
15. A permanent breast seed implant as partial breast radiation therapy for early-stage patients: a comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations.
Keller B; Sankreacha R; Rakovitch E; O'brien P; Pignol JP
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):358-65. PubMed ID: 15890575
[TBL] [Abstract][Full Text] [Related]
16. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
17. [Technique of intraoperative planning in prostatic brachytherapy with permanent implants of 125I or 103Pd].
Prada Gómez PJ; Juan Rijo G; Hevia Suarez M; Abascal García JM; Abascal García R
Arch Esp Urol; 2002 Dec; 55(10):1217-23; discussion 1223-4. PubMed ID: 12611219
[TBL] [Abstract][Full Text] [Related]
18. A radiation badge survey for family members living with patients treated with a (103)Pd permanent breast seed implant.
Keller BM; Pignol JP; Rakovitch E; Sankreacha R; O'Brien P
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):267-71. PubMed ID: 17967512
[TBL] [Abstract][Full Text] [Related]
19. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
20. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
